A Requirement for Ankyrin Binding to Clathrin during Coated Pit Budding*

Abstract

Recent studies suggest that the mobility of clathrin-coated pits at the cell surface are restricted by an actin cytoskeleton and that there is an obligate reduction in the amount of spectrin on membranes during coated pit budding. The spectrin-actin cytoskeleton associates with membranes primarily through ankyrins, which interact with the cytoplasmic region of numerous integral membrane proteins. We now report that the fourth repeat domain (D4) of ankyrinR binds to the N-terminal domain of clathrin heavy chain with high affinity. Addition of peptides containing the D4 region inhibited clathrin-coated pit budding in vitro. In addition, microinjection of D4 containing peptides blocked the endocytosis of fluorescent low density lipoprotein (LDL). AnkyrinR peptides that contained repeat domains other than D4 had no effect on either in vitro budding or internalization of LDL. Finally, immunofluorescence shows that ankyrin is uniformly associated with endosomes that contain fluorescent LDL. These results suggest that ankyrin plays a role in the budding of clathrin-coated pits during endocytosis.

Footnotes

  • * This work was supported by National Institutes of Health Grants DK29808 and HL20948 and the Perot Family Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • § To whom correspondence should be addressed: Dept. of Cell Biology and Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75235-9039. Tel.: 214-648-2576; Fax: 214-648-7577; E-mail: Michaely@utsw.swmed.edu.

  • Abbreviations:
    mAb

    monoclonal antibody

    LDL

    low density lipoprotein

    DTT

    dithiothreitol

    BSA

    bovine serum albumin

    RIA

    radioimmune assay

    PBS

    phosphate-buffered saline

    FITC

    fluorescein isothiocyanate

    PMCA

    3-pyrenemethyl-23,24-dinor-5cholen-22-oate-3β-yl oleate

    ALLN

    N-Ac-Leu-Leu-norleucinal

    HLPPS

    human lipoprotein poor serum

    • Received June 22, 1999.
    • Revision received September 9, 1999.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement